Amorphex Therapeutics

Amorphex Therapeutics is a private ophthalmology-focused healthcare company developing sustained ocular drug delivery technology. Its core asset is TODDD, a soft, non-invasive topical ophthalmic drug delivery device designed to sit under the eyelid and continuously deliver drugs to the eye for weeks to months, with the goal of improving adherence and reducing side effects associated with eye drops. The company is targeting applications in glaucoma and other ophthalmic conditions where chronic topical treatment is limited by poor compliance or inadequate dosing. Amorphex describes TODDD as a platform technology that may also support retinal disease and myopia progression programs. The company appears to be seeking clinical-stage financing and strategic partnering or licensing opportunities to advance its pipeline.